SOFI is participating in the LESS GERD clinical study of the EndoStim system. The LESS GERD study is being conducted at multiple sites across the U.S. to evaluate the effect of the EndoStim system on reflux patients who continue to have symptoms like heartburn and regurgitation despite taking medication every day.
The EndoStim system is a new, minimally-invasive approach to treating gastroesophageal reflux disease (GERD) by neurostimulation. GERD occurs when stomach acid or other stomach contents flow back into the esophagus, often caused by a weak valve, or sphincter, between the esophagus and the stomach. The backwash (reflux) irritates the lining of the esophagus and causes GERD. The EndoStim system is designed to restore the function of this sphincter. The procedure is designed to be uniquely gentle – to keep your anatomy intact and reduce or avoid chances of gastrointestinal side effects.
Most individuals with GERD are successfully treated with acid blocking medications called proton pump inhibitors (PPI), such as Nexium, Prevacid or Prilosec. However, nearly 30 percent of individuals on PPI medication continue to suffer from symptoms. If you are taking PPI medications every day but your symptoms do not completely go away, or if you experience side effects from the medication, you may be eligible for the LESS GERD trial.
Dr. Bell’s study staff can be reached at 303-788-7700 to answer any questions regarding the LESS GERD study.